A detailed history of Pfs Partners, LLC transactions in Cassava Sciences Inc stock. As of the latest transaction made, Pfs Partners, LLC holds 200 shares of SAVA stock, worth $470. This represents 0.0% of its overall portfolio holdings.

Number of Shares
200
Previous 200 -0.0%
Holding current value
$470
Previous $2.47 Million 138.3%
% of portfolio
0.0%
Previous 0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Nov 30, 2023

BUY
$36.77 - $90.91 $7,354 - $18,182
200 New
200 $8.74 Million

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $94.2M
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Pfs Partners, LLC Portfolio

Follow Pfs Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pfs Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pfs Partners, LLC with notifications on news.